Bayer's trial flop, courtroom setback could restrict CEO's options amid strategic review: analyst

After suffering setbacks in the clinic and in court over the last week, Bayer’s ability to overhaul its corporate structure is becoming more constricted, one group of analysts contends.

Still, the German conglomerate is trying to keep its head up as it presses on with a strategic review under new CEO Bill Anderson.